The Federal Drug Administration (FDA) made an exciting announcement this week with the first approval for PARP inhibitors to be used for patients following their initial diagnosis and treatment to reduce the risk of recurrence. The FDA approved the use of the PARP inhibitor olaparib (Lynparza®) for frontline maintenance therapy for advanced epithelial ovarian, fallopian […]
Read More
PARP inhibitors represent an important new class of anticancer agents that are having a major impact on ovarian cancer treatment. These drugs target vulnerabilities in DNA damage response and repair pathways especially in cancer cells that have defects in BRCA and related genes. In an important clinical development announced April 6, 2018, the FDA expanded […]
Read More